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Abstract 
 
From a risk assessment perspective, DNA-reactive agents are conventionally assumed to have 
genotoxic risks at all exposure levels, thus applying a linear extrapolation for low-dose 
responses.  New approaches discussed here, including more diverse and sensitive methods for 
assessing DNA damage and DNA repair, strongly support the existence of measurable regions 
where genotoxic responses with increasing doses are insignificant relative to control.  Model 
monofunctional alkylating agents have in vitro and in vivo datasets amenable to determination of 
points of departure (PoDs) for genotoxic effects.  A session at the 2013 Society of Toxicology 
meeting provided an opportunity to survey the progress in understanding the biological basis of 
empirically-observed PoDs for DNA alkylating agents.  Together with the literature published 
since, this review discusses cellular pathways activated by endogenous and exogenous alkylation 
DNA damage.  Cells have evolved conserved processes that monitor and counteract a 
spontaneous steady-state level of DNA damage.  The ubiquitous network of DNA repair 
pathways serves as the first line of defense for clearing of the DNA damage and preventing 
mutation.  Other biological pathways discussed here that are activated by genotoxic stress 
include post-translational activation of cell cycle networks and transcriptional networks for 
apoptosis/cell death.  The interactions of various DNA repair and DNA damage response 
pathways provide biological bases for the observed PoD behaviors seen with genotoxic 
compounds.  Thus, after formation of DNA adducts, the activation of cellular pathways can lead 
to the avoidance a mutagenic outcome.  The understanding of the cellular mechanisms acting 
within the low-dose region will serve to better characterize risks from exposures to DNA-
reactive agents at environmentally-relevant concentrations. 
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Abbreviations 
AAG: alkyladenine DNA glycosylase 
ATM: Ataxia Telangiectasia Mutated 
BER: base excision repair 
BPD: Break Point Dose  
BMD: benchmark dose  
BMDL: benchmark dose lower confidence limit  
CSBP: computational systems biology pathway 
DSB: double strand breaks  
DDR: DNA damage response   
DRCs: DNA repair centers  
EMS: ethylmethanesulfonate  
ENU: ethylnitrosourea  
FYDR: Fluorescent Yellow Direct Repeat  
HR: homologous repair 
MGMT: methylguanine methyl transferase  
MMS: methylmethane sulfonate  
MNNG: nethylnitronitrosoguanidine  
MNU: methylnitrosourea 
MPG: methylpurine glycosylase 
MN: micronucleus/micronuclei  
MMR: mismatch repair  
MOA: mode-of-action  
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N3-MeA: N-3-methyladenine  
N7-MeG: N-7-methylguanine  
NCS: neocarzinostatin 
NRC: National Research Council  
NOGEL: no-observed-genotoxic-effect-level  
NER: nucleotide excision repair  
O
6
-MeG: O
6
-methylguanine  
γ-H2AX: Phosphorylated (gamma) histone H2AX  
PSCs: pluripotent stem cells  
PoDs: points of departure  
PTM: post-translational modification 
QUE: quercitin 
SSB: single strand break 
TLS: translesion DNA synthesis  
 
Keywords: DNA damage; DNA repair; biological pathways; low-dose; dose-response; points of 
departure. 
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1  Introduction 
Under current human health risk assessment practices, DNA-reactive agents are generally 
considered by regulatory agencies to have no thresholds for biological outcomes such as 
mutation and cancer [1]. The debate surrounding the linearity of low-dose effects related to 
genotoxicity and cancer has been on-going for decades. New understanding in biological 
mechanism and mode-of-action (MOA), along with new high-content and high-throughput 
approaches, and increasingly sensitive analytical methods, bring new evidence into this debate. 
New in vivo and in vitro data have demonstrated the existence of non-linear/bilinear dose-
responses for genotoxic effects (i.e. a dose–response curve with a slope not significantly 
different from zero gradient below the estimated threshold or Break Point Dose (BPD)), where 
there is no significant difference in mutant frequency between the spontaneous background of 
control and the low-dose exposure region of DNA-reactive agents [2-6].  In recent years, new 
statistical approaches have also been developed and applied to analyze low-dose results to 
establish whether the dose-response is linear or non-linear/bilinear, derive a point of departure 
(PoD), and determine what impact the spontaneous background genotoxicity should have on risk 
assessment.  These compelling, empirical dose-response data do not address the biological 
underpinnings of mutation at low-dose exposures per se and require focused investigations of the 
MOA behind these non-linear/bilinear dose-responses. For an expressed mutation, several key 
events must occur from the initial DNA adduct formation, including insufficient adduct repair, 
DNA replication and cell division.  Moreover, endogenous DNA adducts are now recognized to 
be ubiquitously present at quantifiable levels in all living tissues. This new perception of the 
background exposome is shifting perspective on what is normal vs. adaptive vs. adverse [7, 8].  
This review discusses the current understanding of biological, mechanistic processes that explain 
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these PoDs, specifically DNA repair and DNA damage response, and complex interactions 
between these pathways. The detailed discussion presented here was initiated during a Society of 
Toxicology 2013 workshop entitled the Biology of the Low-Dose Response for DNA-Reactive 
Chemicals. A clear focus on molecular and biological approaches to defining and understanding 
consequences of DNA damage at the cellular level fits well with the 2007 NRC report, “Toxicity 
Testing in the 21
st
 Century:  A Vision and A Strategy” that envisions a future in which all routine 
testing will use cell-based in vitro assays of toxicity pathways [9, 10].   
 
1.1 Sources of Spontaneous DNA Damage and Cellular DNA Repair Pathways 
 
The genome continuously undergoes damage due to numerous stressors and to the limited DNA 
chemical stability. Even in the absence of any significant exogenous exposure, mammalian cells 
sustain thousands of pro-mutagenic DNA lesions every day. Normal metabolic processes are 
associated with hydrolysis, deamination, alkylation, and oxidation, resulting in base 
damage, single strand breaks (SSB), double strand breaks (DSB), and interstrand cross-links [20-
23].  Under normal conditions, the steady state level of endogenous DNA damage was recently 
estimated at ≥50,000 lesions per cell; the non-instructional and pro-mutagenic abasic sites are the 
most common DNA lesions, present daily at ~30,000 nucleoside sites in DNA per cell [18, 22, 
24].  DNA repair influences the outcome and dose-response of mutation and chromosome 
damage following exposure to DNA damaging agents at all exposure levels [11-15].  DNA repair 
is usually error-free, but there may be rare events where the mis-repair will result in genotoxic 
outcomes.  Under certain conditions or at high exposure doses, DNA repair itself can increase 
mutation [89-92].  Thousands of times per day, in every cell, DNA lesions are repaired by an 
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integrated defense network that includes five major DNA repair arms: base excision repair 
(BER), nucleotide excision repair (NER), mismatch repair (MMR), non-homologous end-joining 
of double strand breaks (NHEJ) and homology-directed repair of DSB, cross-links and broken 
replication forks (homologous repair; HR). Among these repair activities, BER is considered to 
be one of the most active pathways, handling thousands of DNA lesions every day such as the 
major alkylation adducts, oxidized bases, deaminated bases, abasic sites, and SSB and nicks. 
 
This significant and ubiquitous background of pro-mutagenic DNA damage is likely causative 
for the normal range of background mutations [5, 18].  Recent work has begun addressing the 
potential role of endogenous/background DNA damage in background mutagenesis [5, 6, 8, 16-
19].  The Engelward laboratory developed a sensitive mouse model in which HR events at an 
integrated Fluorescent Yellow Direct Repeat (FYDR) transgene give rise to a fluorescent signal. 
This model provided a clearer understanding of HR background activity, effects due to aging, 
and HR response after exposure to exogenous agents. This model demonstrated that background 
rearrangement events in mice accumulate with age at individual rates in different cells and within 
different tissues (Figure 1) [17, 19]. 
 
2  New Methods to Investigate Responses at Low-Dose Exposures 
 
New understanding of, and new techniques for measuring, the many ways in which normal cells 
handle DNA damage have led to consideration of the relationship between low-dose DNA 
damage and DNA repair, in an effort to understand how these processes contribute to cellular 
homeostasis. This revived interest has resulted in significant efforts to collect low-dose data on 
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dose-response for genotoxic effects and to develop interpretive biological models for those 
observed dose-response behaviors for DNA damage and mutational consequences. Some of the 
new methods are discussed below.  
 
2.1 Analytical Approaches for Measuring DNA Adducts 
  
Swenberg et al. [18] developed sensitive analytical approaches to differentiate exogenously- and 
endogenously-induced DNA adducts.  This work demonstrated the ubiquitous presence of a 
multitude of endogenous DNA lesions, including pro-mutagenic ones that are otherwise identical 
to many of those induced by DNA-reactive chemicals.  The demonstrated steady-state of these 
adducts, especially of pro-mutagenic ones, has changed perspective on the assumption of 
mutagenic outcome and, in particular, on the biological plausibility of the one-hit theory for 
carcinogenesis. Clearly, the presence of an adduct does not equal a mutation, and the availability 
of DNA repair activity will play a key role in the ultimate fate of a DNA lesion. The recently 
published data on formaldehyde, demonstrating that low doses of exogenously inhaled 
formaldehyde induced an increase in exogenous adducts present at levels below the structurally 
identical, quantifiable endogenous levels, is leading to a paradigm shift concerning the role of 
such adducts (endogenous and exogenous) in mutation and cancer induction [6, 25].  
 
2.2 High-throughput Investigations of DNA Repair Capacities 
 
High-throughput, high-sensitivity methods have been developed to investigate overall DNA 
repair activity in response to different types of DNA damage [26]. The “CometChip” technique 
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exploits the traditional Comet assay in which damaged DNA is evaluated by its ability to migrate 
away from the nucleus during electrophoresis. The assay simultaneously follows DNA damage 
load over time in a number of cell lines. This method quantifies kinetics and repair capacity 
within different backgrounds at the level of an individual cell. Initial studies demonstrated 
differential sensitivity and kinetics of DNA repair of various human cells in response to DNA 
damaging agents [26].  
 
2.3 Genotoxic Dose-Response Determinations for DNA-Reactive Agents  
 
For quantitative analysis of dose-response relationships for genotoxicity, approaches have been 
developed to derive various PoD metrics [27-29].  The visual shape of the plotted dose-response 
data can under certain circumstances be potentially misleading and uninformative [136].  For all 
dose-response relationships, a region (i.e., low-dose treatment level) exists where the change in 
adverse response with increasing dose will not be significantly different relative to the control 
(background).  The approaches start with obtaining data from assays containing several doses in 
lower end of the dose-response curve where no apparent increase over the background is 
expected in addition to doses in the effect zone.  These experimental measurements are then 
analyzed with appropriate mathematical models and statistical methods to obtain PoD dose-
response predictors, and to define exposure levels associated with the acceptable risk [28, 29].    
 
The collection and analysis of datasets specifically designed to address the low-dose dose-
response for genotoxic chemicals have now accumulated into an impressive body of empirical 
evidence that allows derivation of the no-observed-genotoxic-effect-level (NOGEL, i.e., highest 
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dose with no statistically significant response) and other useful PoDs for genotoxic effects [27-
30].  Indeed several authoritative bodies have accepted non-linear/bilinear dose-response for 
certain DNA-reactive chemicals based on the extensive empirical evidence and subsequently 
have applied a margin-of-exposure approach to their assessment [31-35]. One common element 
across these cases is generation of data to support a hypothesized or demonstrated MOA, a 
framework with less detailed description than that required for establishing mechanism, based on 
identification of key events responsible for the observed effects [36]. There are many well-
understood biological processes that could underpin a non-linear/bilinear dose-response for 
genotoxic effects that include DNA repair processes, redundancy in the genetic code, non-coding 
regions of DNA, processes associated with DNA replication and damage tolerance, DNA 
damage response networks, and apoptosis/cell death [11, 13, 30]. For DNA alkylating agents, the 
involvement of certain DNA repair systems, such as BER, HR, Direct Repair, and MMR, shifts 
the dose-response curve for genotoxic endpoints. These DNA repair systems are well understood 
and will be reviewed here. 
 
3  Alkylating Agents 
 
3.1 Endogenous and Exogenous Sources 
 
Alkylating agents are ubiquitous in the environment and within living cells. Endogenous DNA 
alkylation adducts are considered to be the major contributor to the total background levels of all 
DNA adducts present at steady-state levels in cells [5, 8, 18, 37]. Endogenous alkylating DNA 
adducts can arise from several different sources, for example from metabolic activity of gut 
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bacteria, or as byproducts of lipid peroxidation, or reacting with cellular methyl donors such as 
S-adenosylmethionine, a common cofactor in cellular methylation reactions [38, 39]. Major 
exogenous sources of alkylating agents come from natural and anthropogenic constituents of air, 
water, and food, as well as from tobacco smoke and fuel combustion products [40-42]. 
Therefore, it will be difficult to distinguish a small risk at low-dose exposures within the normal 
distribution of the background range of mutation. Certain alkylating agents are also used as 
chemotherapeutic drugs, with the goal of killing cancerous cells and treating cancer [43].  For 
example, chemotherapeutic agent Temozolomide produces a distribution of DNA adducts similar 
to that of N-methyl-N‟-nitro-N-nitrosoguanidine (MNNG) and methylnitrosourea (MNU) [44]. 
Recently, work has begun addressing the issue of spontaneous/background adducts and 
exogenous ones (Figure 2). 
 
3.2 Alkylation DNA Base Adducts 
 
The most abundant adduct produced by alkylating agents is at the N-7 position of guanine, a site 
that has the highest negative electrostatic potential in DNA (Figure 3) [45]. Adduct profile data 
show that 67% and 82% of adducts induced by methylmethane sulfonate (MMS) and MNNG, 
respectively, are N-7-methylguanine (N7-MeG) adducts [46].  N-7 guanine adducts are not 
cytotoxic or mutagenic as they do not block DNA replication and are not miscoding [47-50].   
 
The next most abundant adduct (<15%) produced by methylating agents is the N-3-
methyladenine (N3-MeA; Figure 3), as the N-3 position of adenine has the second highest 
negative electrostatic potential [45]. MMS is known to produce 11% N3-MeA whereas MNNG 
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produces 12% N3-MeA [46]. Unlike the N7-MeG, unrepaired N3-MeA is highly cytotoxic, 
inhibiting DNA synthesis and preventing the formation of mutation [51, 52]. Alternatively, N3-
MeA was shown to cause low levels of A-to-T transversions [53]. In test systems deficient in 
alkyladenine DNA glycosylase (Aag), Aag
−/− 
cells with a high proportion of N3-MeA progress 
through S-phase more slowly due to the DNA replication-blocking capability of these adducts 
[51].   
 
In double stranded DNA, adducts on the O
6
 guanine position are also prevalent, and are 
produced by the SN1 alkylating agents that demonstrate greater reactivity towards base oxygen 
atoms (Figure 3).  MNNG produces 7% of O
6
-methylguanine (O
6
-MeG), whereas MMS 
produces only 0.3% of O
6
-MeG [46]. O
6
-MeG is the major pro-mutagenic adduct that induces 
G:C to A:T mutations as it readily mispairs with thymine [54]; however, it is also highly 
cytotoxic [55]. As will be discussed later, the mutagenic vs. cytotoxic response to O
6
-MeG lesion 
depends on the status of MMR.  
 
The remaining alkylating lesions occur at 10 to 100-fold lower levels than the previously 
described adducts.  Base sites in double stranded DNA with lesser electrostatic potential are at 
the N-3 position of guanine, O
2
 position of cytosine, N-7 position of adenine, and O
4
 and O
2 
positions of thymine [45]. Alkylation adducts are produced by MMS or MNNG at N-1 and N-7 
positions of adenine, N-1 and N-3 positions of guanine, N-3 and O
2
 positions of cytosine, as well 
as N-3, O
2
 and O
4 
positions of thymine all of these comprise <5% of the total adducts in double 
stranded DNA [46].  The alkylation adducts can cause mutations or block essential biological 
processes such as DNA replication leading to cell death (Figure 3).  It was also demonstrated that 
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specific alkylation lesions (N1-A, N3-A and N3-C) can be both mutagenic and cytotoxic [137].  
Overall, as the spectrum of alkylation DNA base adducts and biological responses to these 
adducts are well understood, it allows for the generation of MOA data and estimation of PoD 
values for this class of chemicals.    
 
3.3 Endogenous vs. Exogenous DNA Base Adducts 
 
Methylating agents provide well-studied examples of the contribution of endogenous and 
exogenous DNA base adducts to background and induced mutation.  Work in D3-MNU-treated 
AHH-1 cells demonstrated linear dose-responses for both exogenous D3-N7-MeG and exogenous 
D3-O
6
-MeG adducts at low-dose exposures, and a steady-state of endogenous/background 
formation (Figure 2; [5]). As the endogenous load of N7-MeG is significant, exogenous adducts 
did not contribute significantly to the total load until the highest concentrations utilized in the 
study. On the other hand, endogenous O
6
-MeG adducts were much less abundant. When 
compared with the mutation dose-response curves, these exogenous O
6
-MeG adducts are likely 
to drive the mutation dose-response above the background/spontaneous mutation frequency [5].   
 
3.4 Genotoxic Dose-Response Datasets 
  
Several datasets exist that offer a detailed view of dose-response for induction of genotoxic 
effects. For alkylating agents, representative studies include three in vitro [56-58] and three in 
vivo [2, 3, 138] low-dose dose-response genotoxic datasets (an example is presented in Figure 4).  
The genotoxic chemicals used in these studies included direct-acting, monofunctional 
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ethylmethanesulfonate (EMS), MMS, ethylnitrosourea (ENU), and MNU, although not all of the 
studies used all four chemicals. All of these studies were designed with an extended number of 
low-dose treatments, and with higher numbers of replicates than is typical for genotoxicity 
studies.  They were conducted with different experimental systems, including gene mutations in 
mammalian cells in vitro (human-derived TK6 and AHH-1 lymphoblastoid cell lines; L5178Y 
mouse lymphoma cells) and in lymphocytes from in vivo exposure of transgenic (lacZ; gpt-delta) 
or normal (Pig-a) mice. Micronuclei (MN) were assessed both in vitro (TK6 and AHH-1 cells) 
and in vivo (mouse bone marrow). All these datasets were statistically evaluated with a 
methodology that directly compared goodness-of-fit of a linear dose-response model to that of a 
non-linear/bilinear dose-response model [27, 29, 59].  These studies demonstrated non-
linear/bilinear dose-response curves for genotoxic effects with the SN2 alkylating agents EMS 
and MMS [3, 56-58] and with the SN1 alkylating nitrosoureas, ENU and MNU [3, 56-58, 60, 61].   
 
The EMS dataset for induction of MN in vivo was a particularly compelling example 
demonstrating a non-linear/bilinear dose-response for genotoxic effects with the biomarker 
hemoglobin adducts being quantified as a measure of internal (systemic) dose in the blood cells 
[3].  The data clearly demonstrated an increasing level of hydroxyethylvaline hemoglobin 
adducts corresponding with increasing administered dose of EMS, but with no increase in 
corresponding MN induced until the administered dose exceeded the 80 mg/kg bw/day dose in 
mouse. Mutational in vivo dose-response with EMS was also recently investigated in adult gpt-
delta transgenic mice within different tissues at the gpt transgene and at the Pig-a endogenous 
gene [2]. In the study, measured mutation NOGELs were identified at below 13 mg/kg/day 
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andthe lowest calculated PoD value, BMDL10, of 0.038 mg/kg/day was found in the lung of gpt-
delta mice.  
 
Furthermore, the mutation induction at the HRPT locus was compared with formation of DNA 
base adducts (Figure 4). The major (N7-MeG) and the key pro-mutagenic (O
6
-MeG) adducts 
were quantified in AHH-1 cells following exposure to 
13
C-MMS [62]. 
13
C-labelled adducts 
increased linearly with the treatment dose. These analytical results were compared with the non-
linear mutational frequency data for HPRT locus obtained under the same low-dose MMS 
treatment [56]. Clear differences in the shape of dose-response curves were seen for exogenous 
adduct formation and mutation induction at low doses, even for pro-mutagenic DNA adducts.  
 
However, these compelling empirical dose-response data do not address the biological 
underpinnings of mutation at low-dose exposures per se, and thus investigation of the MOA 
behind these non-linear/bilinear dose-responses represents a necessary next step.  One proposed 
MOA for mutation describes formation of a pro-mutagenic DNA adduct as an initial/early key 
event [63-65].  However, as adducts do not equal mutations, there are several additional 
necessary key events proposed that require functioning cellular responses such DNA replication 
and cell division, prior to causing a mutation.  Thus, formation of adducts, even pro-mutagenic 
ones, will not necessarily guarantee a mutagenic outcome [66, 67].  
 
3.5 DNA Repair  
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The biological responses to alkylating agents are quite complex due to the variety of alkylation 
adducts produced in DNA, and the variability this imparts to their biological significance [4, 63, 
65, 68].  Under certain conditions such as imbalanced DNA excision or abnormally high levels 
of activity, DNA repair itself can be a cause of mutation [89-92].  Not every adduct is considered 
to be pro-mutagenic whereas adducts that are pro-mutagenic can be processed by a number of 
biological pathways, preventing the formation of mutation. The major repair pathways involved 
in the removal of alkylation adducts have different targets that result in different outcomes 
(Figure 3).   
 
BER is a key DNA repair pathway that removes thousands of DNA lesions every day, including 
alkylated and oxidized bases, SSB, and abasic sites (Figure 5). The BER pathway repairs the N-
alkyl lesions including N3-MeA and N7-MeG.  BER is initiated by DNA glycosylases that 
remove the N-alkyl adducted bases in all species examined [69]. DNA glycosylases of BER 
decrease the half-lives of N7-MeG and N3-MeA in DNA to minutes and ensure that abasic sites 
are processed by BER [70, 71]. Both adducts have rapid rates of spontaneous depurination as 
alkylation of purines destabilizes the N-glycosidic bond and renders these bases more susceptible 
to hydrolysis with half-lives of approximately 30 h and 70 h, respectively, for N3-MeA and N7-
MeG at 39°C [72]. In fact, spontaneous depurination is the major fate of N7-alkyl adducts [48, 
73, 74]. The resulting abasic/apurinic sites can be processed by a number of other repair 
pathways, including HR, NER, or translesion DNA synthesis (TLS), a DNA tolerance pathway 
[75-77]. Indeed abasic sites have been shown to represent the predominant endogenous lesion 
present in DNA at a steady-state, with as many as ~30,000 abasic sites being present per cell [18, 
22, 24]. 
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N3-MeA and N7-MeG adducts also appear to be substrates for the NER pathway [78-80]. Direct 
reversal of DNA damage and TLS are important response pathways for alkylation damage.  
Direct reversal pathways remove adducts from the DNA restoring the original base directly in an 
error-free mechanism. In mammals, two direct repair pathways handle alkylation DNA damage, 
the O
6
 methylguanine-DNA methyltransferase (MGMT) that restores guanine from O
6
-MeG and 
the AlkB homologue (ABH) family of Fe(II)/α-ketoglutarate dioxygenases that directly repair 
alkylation damage in DNA and RNA at base-pairing sites [81]. In contrast, TLS continues DNA 
replication across the adducted base blocks encountered by replicative DNA polymerases, either 
in an error-free or an error-prone manner. 
 
Manipulation of DNA repair activities in cells with molecular biology approaches resulted in a 
shift in the PoD values following treatment with alkylating agents, thus demonstrating a key role 
for DNA repair in PoDs for mutational/genotoxic effects [61, 82].  
 
3.6 DNA Damage Response Pathways 
 
DNA stress response pathways, both p53-dependent and p53-independent, are also activated in 
an effort to counteract DNA damage induced by alkylating agents. These can remove cells 
harboring DNA damage from the population. ATM signaling kinase and p53 tumor suppressor 
are key players in DNA damage signaling pathways, activated in response to DNA lesions. 
Apoptosis induced by the key mutagenic and cytotoxic adduct, O
6
-MeG, can proceed 
independently of ATM and p53 [83-85].  N-alkyl lesions can also trigger apoptosis via p53-
independent pathways [86]. Thus, as cells continually deal with endogenous/background DNA 
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alkylation, the existence of mutational thresholds at low exposures/doses is not surprising and 
can be explained based on the adaptive and homeostatic responses known to operate in biological 
systems in response to these stressors.     
 
4  DNA Repair and Break Point Doses 
 
Manipulations of DNA repair activity have been known to influence genotoxicity and cancer 
predisposition. Two prototypical types of DNA-reactive agents are discussed below.   
  
4.1 Alkylation DNA Damage 
 
Methods to investigate the influence of DNA repair on low-dose genotoxic outcomes were 
developed in Johnson‟s laboratory, such as DNA glycosylase knockdown [61]. Gene expression 
analysis has been used in cell lines with inhibited DNA repair activity to investigate the potential 
links between specific DNA repair pathways and shifts in PoDs, such as NOGELs, for gene 
mutation and chromosome damage endpoints. This integrated methodology has linked 
methylpurine glycosylase (MPG)/AAG DNA glycosylase to a shift in the NOGEL for MN 
induction in the human-derived lymphoblastoid AHH-1 cell line following exposure to EMS 
[82]; a causal role has not been documented for any specific EMS-induced DNA adduct in MN 
induction.  An increase in MPG/AAG glycosylase gene expression occurred above and below 
NOGEL for chromosome damage as measured through MN induction at certain time points, but 
not for the HPRT gene mutation dose-response [82].  This small decrease in gene mutation 
frequency slope in treated cells is in line with evidence that suggests decreased repair of certain 
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alkylation lesions could be protective against mutagenic and cytotoxic effects of abasic site and 
SSB BER intermediates [86-88]. 
 
For the pro-mutagenic O
6
-MeG adduct derived from MNU treatment, a clear link between the 
levels of MGMT repair protein (discussed below) and the HPRT gene mutation PoD/NOGEL 
metric was seen in human-derived AHH-1 cells [61]. This effect was manifested as a shift in the 
PoD/NOGEL to a lower MNU dose when MGMT was pre-depleted with O
6
-benzylguanine. 
Thus, decreased MGMT repair activity reduced the PoD value following MNU treatment 
compared to PoD obtained with MNU treatment under normal repair conditions.  Sequencing of 
the HPRT mutants showed the expected increase in O
6
-MeG-induced G-to-A transitions. Even 
though the mechanisms of action differ for chromosome breaks compared to gene mutation, 
these differences are likely due to specific DNA lesions and repair by their respective DNA 
repair pathways. Nonetheless, the underlying MOAs behind the demonstrated shifts in NOGELs 
and PoDs for both endpoints appear to rely upon changes in DNA repair capacity.  
 
4.2. Double Strand DNA Damage 
 
DSBs are induced by variety of agents, including ionizing radiation, radiomimetic drugs and 
alkylating agents. HR is an essential pathway for resolution of broken replication forks and DSB 
in the S/G2 phases of the cell cycle whether they result from endogenous or exogenous 
processes. HR can be stimulated by DSB, DNA nicks and increased levels of abasic sites (Figure 
5). Rare errors in HR repair may result in sequence rearrangements and loss of heterozygosity, 
two prominent features of tumor cells. Since HR and BER pathways are active in response to 
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spontaneous DNA damage, they would respond to low-dose radiation and genotoxic chemicals. 
Both pathways are usually error-free, but there may be rare events where there are misalignments 
during HR and misinsertions during BER that result in genotoxic outcomes. The level of DNA 
repair activity is tightly controlled at the cellular level as too much or too little repair activity of 
either of these pathways can lead to increases in genotoxic outcomes [89-92].  
 
Biological consequence of low-dose γ-radiation, the prototypical agent that induces HR, was 
explored by Olipitz et al. [93].  This work evaluated several endpoints such as accumulation of 
DNA damage, sequence rearrangements, and gene expression, following whole body exposure to 
low doses of radiation. The innovative exposure apparatus made it possible for mice to live in the 
continued presence of radiation at exposures that were approximately 400-fold higher than 
background for an extended period of time. The exposure to 10.5 cGy is expected to induce 
additional ~400 base lesions per cell [93]. Using these sensitive techniques, non-linear/bilinear 
dose-response relationships were observed for several biomarkers following these low-level 
radiation exposures. After exposure to 400-fold background radiation for five weeks, there was 
no evidence of any increase in key DNA base lesions in mouse tissues, no increase in DSB, or in 
HR events (Figure 6). Importantly, when the same total amount of radiation was given in one 
acute dose, rather than over a 5-week timeframe, DSB and DNA stress responses were in fact 
detected. Clearly, dose-rate is a critical factor when considering the adverse consequences of 
low-dose exogenous exposures, presumably because DNA repair keeps up with and repairs DNA 
damage at low doses, whereas at high exposure doses, available DNA repair capacity is 
overwhelmed and can lead to adverse outcomes including mutation.  Importantly, the original 
paradigm for the one-hit theory in fact came from very early studies with γ-radiation, the same 
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DNA damage inducer as that used by Olipitz et al. [93] to show non-linear/bilinear dose-
responses [93, 94].  
 
5  Interactions between DNA Repair and DDR Pathways 
 
The realization that complex interactions exist between different DNA repair pathways is an 
important development. These complex biological relationships can combine to manifest as the 
non-linear dose-response for genotoxic effects. 
 
5.1 BER and HR 
 
The Engelward laboratory has focused on the ways in which one DNA repair pathway affects 
another. For instance, excessive activity in one pathway creates repair intermediates that 
stimulate a different pathway. This paradigm is evident in the interactions between BER that 
promote HR events (Figure 5).  The Engelward laboratory has shown that conditions inhibiting 
the initiation of BER actually suppress HR in vivo, presumably because the BER intermediates 
(including SSB or abasic sites) are more recombinogenic than some of the original adducted base 
substrates of BER [95]. These results show that changes in the balance of activity and protein 
products in one pathway (BER) can affect processing via another pathway (HR) and may put 
cells at increased risk of mutation.  
 
5.2 MGMT and MMR 
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Another well-studied network of repair pathways handles the pro-mutagenic O
6
-MeG adducts. 
Exposure to SN1 MNNG or MNU nitrosoureas results in a variety of DNA base lesions. The 
most toxic of these is O
6
-MeG, produced at <10% of all nitrosourea-induced alkylated bases 
[46]. Repair of this adduct involves the DNA MGMT protein, which directly transfers the methyl 
group from O
6
-MeG to its active site‟s cysteine, followed by ubiquitin-mediated degradation of 
the now-methylated MGMT protein [96, 97]. When levels of MGMT are not adequate or 
depleted, the MMR pathway serves as a backup repair pathway by eventually eliminating cells 
with O
6
-MeG bases and preventing mutation (Figure 7). If the cells enter S-phase prior to O
6
-
MeG repair, the DNA polymerase commonly mispairs O
6
-MeG with thymine resulting in a O
6
-
MeG:T mismatch and fixation of a G-to-A transition mutation in the second round of replication.  
This new mismatch, however, is readily recognized by the heterodimer MSH2-MSH6 of the 
MMR pathway [98].  SCEs, chromosomal aberrations, and HR events can also be induced by O
6
-
MeG adduct via an MMR-dependent pathway [99-104].  Under normal circumstances, MMR 
repairs spontaneous single-base mispairs and small insertion or deletion loops created by the 
DNA polymerase during replication; loss of MMR function results in a nearly 1000-fold increase 
in spontaneous mutation rate [105].   
 
5.3 MMR and DDR 
 
In addition to its role in post-replication repair, MMR also responds to certain forms of DNA 
damage including alkylation damage, where MMR brings about the induction of cell cycle 
checkpoints and apoptosis by one of two proposed models; either by futile cycling [106-108] or 
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direct signaling. The direct signaling model is supported by observed interactions between 
MSH2 or MLH1 with signaling kinases such as ATM, ATR, CHK1, and CHK2 [109-112]. 
 
MMR proteins MSH2 and MLH1 were shown to be recruited to chromatin containing the O
6
-
MeG:T mismatches in a number of in vitro cell systems during the first S-phase following 
exposure [113]. The cells typically complete another round of the cell cycle before arresting in 
the second G2/M phase after damage [108, 114]. MSH2 and its partner MSH6 recognize O
6
-
MeG:T mismatches, following MSH2/MSH6 heterodimer conversion to an ATP-dependent 
sliding clamp on DNA, and recruit the second MMR heterodimer of MLH1-PMS2. Together, 
these MMR complexes coordinate excision of the newly synthesized daughter strand and re-
synthesis across from the O
6
-MeG adduct by exonuclease (Exo) I [115-118]. The replication 
activity also involves the function of the polymerase processivity factor PCNA which co-
immunoprecipitates with MSH2 and MLH1 on damaged chromatin in the first S-phase [113]. In 
the futile cycle model [119, 120], the repeated processing of the O
6
-MeG:T mismatch by the 
MMR pathway results in prolonged single strand nicks or unreplicated gaps that remain past S-
phase through to the next cell cycle.  As the replication fork encounters these sustained nicks 
and/or gaps in the second S-phase after treatment, they are converted into DSBs and activate 
DNA damage response signaling cascades, including CHK1 and CHK2 DNA damage response 
kinases in the second S-phase after damage [85, 108, 113]. Moreover, results from the Heinen 
laboratory also raise the possibility that the continued presence of MSH2 and MLH1 on 
chromatin in the second cell cycle may serve as protein blockades that impede replication fork 
progression during the second S-phase leading to DNA damage response. Interestingly, in 
pluripotent stem cells (PSCs), MMR-dependent alkylation damage response results in a robust 
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apoptotic response that occurs in the first S-phase after DNA damage [121]. These results 
indicate either that that PSCs are extremely sensitive to perturbations in DNA replication caused 
by iterative MMR cycles, or that MMR proteins may be involved in direct signaling of damage 
immediately upon recognition in the first cell cycle.  
 
Collectively, these results provide evidence that cells utilize multiple DNA repair mechanisms to 
protect themselves from the threat of endogenous and exogenous mutagenesis caused by 
alkylating agents. In addition, DNA damage responses in different test systems may differ while 
still functioning together to prevent formation of mutation.  
 
6  Profiling of Biological Pathways and Genotoxic Dose-Response Relationships  
 
High-throughput and high-content assays can inform on chemical-specific perturbations of 
toxicity pathways.  Cells respond to physical and chemical stressors by activating signal 
transduction cascades that can lead to various cellular outcomes or even cell death.  These 
biological outcomes can be analyzed together and modeled in order to predict the BPD for 
mutational outcomes in relation to activation of various biological pathways.  
 
6.1 Computational Approaches 
 
Cellular repair foci arising from protein recruitment to sites of DNA damage are necessary to 
complete lesion repair and reduce the probability of mutation. The molecular mechanisms 
involved in formation of these complexes, dependent on phosphorylation status and protein 
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abundance, are expected to be key determinants of the repair and mutational outcome at the low-
dose exposures. Increasing knowledge of the interplay of these processes can guide construction 
of predictive computational systems biology pathway (CSBP) models of mutational outcome that 
can provide mechanistic understanding of BPD behaviors [122]. The p53-mdm2 stress response 
pathway is a key cellular stress response whose dynamics should serve as the underpinning for 
the mechanistic basis of non-linear/bilinear dose-response for mutagenesis [123]. Hamner-
Unilever work on DNA damage pathway modeling networks has developed from a case study 
approach for implementing key recommendations from the 2007 NRC report, Toxicity Testing in 
the 21
st
 Century: A Vision and A Strategy [9].  The merits of case study approaches for DNA 
damage assessment were outlined earlier and a more complete discussion of the approach for 
consumer product applications has recently appeared [124, 125]. 
 
6.2 Transcriptome Responses of Biological Pathways  
 
To develop a robust dataset for understanding the p53-mdm2 pathway mechanistically, Hamner 
and Unilever have used the HT1080 human-derived fibrosarcoma cell line with wild-type p53 
protein, to investigate p53-mdm2 pathway activation.  Cells were exposed to a variety of 
compounds, including SN2 alkylator MMS, topoisomerase inhibitor etoposide (ETP) inducing 
DSB, -irradiation mimic neocarzinostatin (NCS) producing DSB, and quercetin (QUE), a 
polyphenol [126]. The CSBP model construction began using a simple negative feedback stress 
response pathway model designed to account for either proportionate control or perfect 
adaptation [127].  In proportionate control, there is some, small increase in response (e.g., 
mutation rate or MN formation) to an increasing stressor level. Perfect adaptation is the ability of 
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a cell or an organism to maintain a constant net level of damage (i.e., mutation rate) throughout a 
range of increasing stressor and is capable of producing a threshold response [128].   
 
To fill out details of these DNA-repair and DDR networks, a high coverage approach, measuring 
whole genome transcriptomics and various proteins/phosphorylated proteins in the pathway, 
including p21, mdm2, p53, phospho-p53 (ser-15) and γ-H2AX was used. In addition, cell cycle, 
apoptosis, necrosis, and MN were also quantified over a broad, 18-point dose range spanning a 
low-dose range for mutational PoD. These data streams and representation of the changes in the 
signaling pathway were visualized using a composite suite of endpoints shown in increasing 
color intensities to capture the changes between compounds and across doses [126]. 
 
6.3 Genotoxic Responses 
 
The dose-response for MN formation with MMS, under low-dose exposure conditions, showed 
evidence of a non-linear/bilinear dose-response [59]. Surprisingly, the lowest observed genotoxic 
effect levels for MN formation were similar to or even lower than those identified for the 
markers of the p53 pathway, including gene expression, protein modification, and cell-based 
measures of response (Figure 8). In addition, no significant gene expression changes at dose 
levels below the benchmark doses (BMDs)/PoDs for MN formation were seen with any of the 
test compounds employed in the study.  With MMS, there were few transcriptional responses in 
the region of the MN-BMDL (Figure 9).  Feedback models of perfect adaptation involving 
transcriptional regulation of repair genes and p53 pathway components were not at all consistent 
across these experimental results.  In the work with MN, control of mutagenicity following low 
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levels of DNA damage did not arise from cell cycle arrest, apoptosis, or up-regulation of DNA 
repair genes.  All of these cellular pathways had BMDs similar to or greater than those for MN 
formation. Previous work had already shown that transcriptional regulation in response to DNA-
damage was a high dose phenomenon and unlikely to be responsible for bilinear curves [129].  
Surprisingly, none of the evaluated markers had BMDs below those for MN formation.   
 
6.4 Post-Transcriptional Modification 
 
The next steps in the development of DNA-damage pathway dose-response modeling moved 
toward consideration of processes that contained two regulatory responses. One pathway was the 
transcriptional activation at higher doses coupled with a more rapid-responding, lower dose 
pathway involving activation of repair through post-translational modifications of existing repair 
proteins [130]. A post-translational modification (PTM) for DNA repair may serve as a negative 
feedback loop to enhance repair rates through increased formation of DNA repair centers 
(DRCs) [131]. In this two-pathway DNA-repair circuitry, both arms required p53 forming repair 
centers at low DNA damage levels, or as a tetrameric transcription factor at high levels (Figure 
10).  Idealized model for perfect adaptation demonstrated thresholds occurred when zero-order 
degradation of key phosphoproteins involved in the DRC formation/maintenance were included.  
Progress in examining the biological basis of bilinear responses with MMS will likely require 
better tools to look at formation, resolution and persistence of the DRCs after low-dose 
treatments.   
DRCs formation was also examined after treatment with NCS.  The dose-response following 
treatment with NCS was strikingly bilinear.  With this compound, there were increases in DRCs 
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at doses below those causing mutations.  The resolution of DRCs at sub-threshold doses for MN 
with NCS was rapid, but became much slower at doses that increased MN formation (Figure 11).  
Examination of DRC kinetics following treatment with various DNA-damaging agents has to 
become more common to allow the development of a mechanistic understanding of BPD.  This 
work to date indicated that the threshold behaviors noted with DNA-damaging agents most likely 
arise due to post-translational activation of DRCs accompanied by processes such as zero-order 
clearance of components of the repair centers [132]. 
 
7  Conclusions 
There is significant interest in understanding the contribution of biological mechanisms to the 
non-linear/bilinear dose-response curves for DNA-reactive agents. Model monofunctional 
alkylating agents have datasets amenable to PoD determination for genotoxic effects in both in 
vitro and in vivo tests systems; these findings were supported by robust statistical analysis of in 
vitro and in vivo datasets [27-30].  Such new experimental and computational approaches will 
help develop mechanistic evidence to support the necessary, biological understanding of the 
MOA for empirically demonstrated PoDs for DNA-reactive agents.  The biological evidence for 
alkylating agents points to multiple DNA repair systems and DDR pathways acting together to 
prevent mutation, giving rise to non-linear/bilinear dose-responses for genotoxicity. Complex 
interactions within a particular DNA repair pathway, as well as interplay between different DNA 
repair and DDR pathways, counteract the effects of ever-present background DNA damage. 
Together, these pathways appear sufficient to counteract mutation at low exposures/doses and/or 
the propagation of cells harboring significant DNA damage. The interplay of these biological 
processes serves as the basis of non-linear/bilinear dose-responses for genotoxic effects.  
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Continuing efforts should be increasingly focused on the biological underpinnings of PoDs in 
order to show the biological pathways/networks involved in repair and homeostatic processes for 
various types of DNA damage. Hence, the examination of these key cellular, mechanistic 
responses should be integrated into the designs of the MOA studies to demonstrate the PoDs for 
genotoxic effects for various types of DNA-reactive agents. These diverse data streams can then 
be applied to risk assessment for genotoxic chemicals to reduce overall uncertainty in the 
process, specifically for risk characterization and uncertainties surrounding exposures at 
environmentally-relevant concentrations.   
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Figure Captions 
 
Figure 1.  Mutant cells accumulate with age in tissues under normal conditions. Wiktor-
Brown et al. [19]  investigated the effects of aging on the frequency of HR events in the FYDR 
mice. In pancreas, 23-fold increase in recombinant cell frequency with age was noted in vivo.  
 
Figure 2.  Dose-response for endogenous and exogenous methylating adducts. Endogenous 
(unlabeled) and exogenous (D3-labelled) N7-MeG and O
6
-MeG were measured after treatment 
with D3-MNU in AHH-1 cells (from Sharma et al. [5]). Exogenous N7-MeG adducts did not 
significantly contribute to the total N7-MeG adduct load under low-dose treatment conditions.  
 
Figure 3.  Overlapping DNA repair systems are involved in removal of alkylation DNA 
adducts. BER and MGMT substrates are also handled by NER.  Unrepaired damage or repair 
intermediates can be funneled to tolerance mechanisms HR, NHEJ or TLS. Black arrows 
indicate adducts induced in significant proportion by SN1 alkylating agents only. White arrows 
indicate adducts induced by both SN1and SN2 alkylating agents. Arrow thickness correlates with 
the frequency of induced adducts. Adapted from Wyatt and Pittmann [69]. 
 
Figure 4.  Dose-response curves for mutation and DNA adducts.  Exogenous N7-MeG and 
O
6
-MeG adducts were measured following 24 hour treatment with 
13
C-labelled MMS [62]. 
Adducts demonstrated linear dose response. Mutation induction at HPRT locus, demonstrating 
bilinear dose-response, with similarly treated AHH-1 cells was taken from Doak et al. [56]. 
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Figure 5.  Repair of alkylated DNA bases by the BER repair pathway and channeling of 
DNA repair intermediates into the HR pathway during DNA replication. Unrepaired DNA 
adducts, abasic sites, gaps and DNA nicks in S-phase are handled by the HR pathway.  
 
Figure 6.  No detected changes in DNA damage or responses after repeated exposure to low 
level radiation.  After continuous exposure over 5 weeks to 0.0002 cGy/min radiation (400-fold 
over background radiation), the exposed mice did not demonstrate increased levels of DNA 
nucleobase damage (hypoxanthine, 8oxoG, 1,N6-ethenoadenine, or 3,N4-ethenocytosine) or 
DNA fragmentation (MNT assay and double strand break–induced HR) above background 
levels. In addition, low dose-rate radiation did not induce Cdkn1a, Gadd45a, Mdm2, Atm, or 
Dbd2 gene expression before and after irradiation (from Olipitz et al. [93]). The same total dose 
delivered acutely induced both MN and transcriptional responses. 
 
Figure 7.  Cellular processing and repair of O
6
-MeG adducts in DNA. MGMT directly 
repairs O
6
-MeG adducts. If unrepaired, O
6
-MeG preferably mispairs with T during DNA 
replication leading to G:C-to-A:T transitions. Alternatively, O
6
-MeG lesion induces apoptosis 
via an MMR-dependent pathway. O
6
-MeG/MMR-dependent DNA damage response includes 
multi-pathway, multi-time scale signaling network activation led by early ATM, H2AX, ATR-
CHK1, and p53 phosphorylation, then followed by late phosphorylation of ATM-CHK2 and 
JNK kinase, as well as dramatic increases in p53 levels and p53 transcriptional targets [85].  
Sister chromatid exchanges (SCE) and chromosomal aberrations are induced by O
6
-MeG lesions 
via an MMR-dependent pathway in the second cell cycle [102]. The gaps and nicks present 
during this phase can form DSB that are handled by HR. With loss of MMR, cells become 
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“methylation-tolerant” accumulating mutations and escaping cell death in the presence of 
unrepaired O
6
-MeG.  
 
Figure 8.  Comparison of responses across endpoints for DNA damage response for three 
DNA-damaging compounds.  Values shown are for BMDLs (lower 95% confidence limit for 
BMD).  For each chemical, MN induction (purple) occurred at lower doses than gene 
transcription changes (orange).  With MMS, the BMDL for the transcriptional activation was 
closest to the MN-BMDL for any of the compounds, but was still greater than the MN-BMDL. 
 
Figure 9.  Organization of gene transcriptional changes 24 hr after treating HT-1080 cells 
with various concentrations of MMS.  Cells were treated with up to 500 M MMS. Responses 
at key doses are presented. The union of all significantly changed genes was used to assess all 
GO ontology categories that were significantly enriched at any treatment.  This organization 
provided the structure of categories shown by the various encircled patterns.  The colors, green 
(up-regulated) and purple (down-regulated), show the groupings that were significantly changed 
at each treatment and the size of circles represents the numbers of genes changed in particular 
GO-categories. At 100 M, the transcriptional changes were minimal even though this 
concentration was 10-fold above the MN-BMDL.  The visualization tools were developed in 
work with nuclear receptors [133, 134]. 
 
Figure 10.  Computational Model for Threshold Response. A working model explaining 
threshold responses, demonstrated for MN formation with increasing exposures, has two 
response pathways – a fast acting, post-translational pathway that works to maintain  perfect 
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control (and threshold behaviors) and a transcriptional pathway with p53 tetramer that 
contributes at much higher levels of damage (thus higher doses), after there is an increase in MN 
formation. 
 
Figure 11.  Time-Course Behaviors of DNA-Repair Centers (DRCs) at low and higher 
doses.  Top:  Images of DRC foci in control nuclei.  Middle section: images of DRCs following 
treatment with very high doses of NCS.  The foci in individual nuclei show the co-location of 
two repair proteins – p53 binding protein and-H2AX.  Lower left: dose- and time-response for 
DRCs (as foci per nucleus) following treatment with NCS.  At lower concentrations (left), foci 
resolve quickly.  At higher concentrations, DRCs persist out beyond 24 hrs.  The lower doses are 
in the sub-threshold region for MN-formation and the higher doses are those with increased MN 
frequencies.  Plots are representative of studies reported in other work from the Hamner-Unilever 
collaboration [135]. 
  
53 
 
 
  
54 
 
 
  
55 
 
Figure 3. 
 
  
56 
 
 
  
57 
 
 
  
58 
 
 
  
59 
 
 
  
60 
 
 
  
61 
 
Figure 9. 
 
  
62 
 
 
  
63 
 
 
